Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Sep 19;10(9):340.
doi: 10.3390/cancers10090340.

Autologous Transplantation for Older Adults with AML

Beatrice U Mueller  1 , Katja Seipel  2 , Ulrike Bacher  3 , Thomas Pabst  4
Affiliations
Review

Autologous Transplantation for Older Adults with AML

Beatrice U Mueller et al. Cancers (Basel). .

Abstract

While the majority of patients with acute myeloid leukemia (AML) are above the age of 65 years at diagnosis, the outcome of older AML patients remains disappointing. Even if standard intensive chemotherapy induces morphologic complete remission (CR1), relapses in older AML patients are common leading to poor long-term survival outcomes. Since autologous hematopoietic stem cell transplantation (HCT) offers distinct anti-leukemic effectiveness while avoiding graft-versus-host disease associated with allogeneic transplantation, it represents an option for consolidation treatment in selected older AML patients. However, prospective studies in older AML patients assessing the benefit of autologous HCT compared to chemotherapy consolidation or allogeneic transplantation are lacking. Consequently, clinicians face the dilemma that there is considerable ambiguity on the most appropriate consolidation treatment for older AML patients in CR1. This review highlights the possible role of autologous HCT for consolidation in older AML patients reaching CR1 after induction treatment.

Keywords: AML; autologous; elderly; older; outcome; review; survival; transplantation.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Kaplan Meier curves depicting the overall (OS) and progression-free survival (PFS) of 148 consecutive patients receiving autologous hematopoietic stem cell transplantation in first complete remission of AML. Above, survival outcomes (A,B) of all patients are shown. Below (C,D), patients are grouped according to age below 60 years (n = 103 patients; blue curves), between 60–64 years (n = 27; red curves), and 65 or more years (n = 18; green curves). PFS: progression-free survival; OS: overall survival.
See this image and copyright information in PMC

References

    1. Dohner H., Weisdorf D.J., Bloomfield C.D. Acute myeloid leukemia. N. Engl. J. Med. 2015;373:1136–1152. doi: 10.1056/NEJMra1406184. - DOI - PubMed
    1. Ossenkoppele G., Lowenberg B. How I treat the older patient with acute myeloid leukemia. Blood. 2015;125:767–774. doi: 10.1182/blood-2014-08-551499. - DOI - PubMed
    1. Lowenberg B., Ossenkoppele G.J., van Putten W., Schouten H.C., Graux C., Ferrant A., Sonneveld P., Maertens J., Jongen-Lavrencic M., von Lilienfeld-Toal M., et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N. Engl. J. Med. 2009;361:1235–1248. doi: 10.1056/NEJMoa0901409. - DOI - PubMed
    1. Vellenga E., van Putten W., Ossenkoppele G.J., Verdonck L.F., Theobald M., Cornelissen J.J., Huijgens P.C., Maertens J., Gratwohl A., Schaafsma R., et al. Autologous peripheral blood stem cell transplantation for acute myeloid leukemia. Blood. 2011;118:6037–6042. doi: 10.1182/blood-2011-07-370247. - DOI - PubMed
    1. Cornelissen J.J., Blaise D. Hematopoietic stem cell transplantation for patients with AML in first complete remission. Blood. 2016;127:62–70. doi: 10.1182/blood-2015-07-604546. - DOI - PubMed